The Pershing Square Sohn Cancer Research Alliance is dedicated to playing a catalytic role in accelerating cures for cancer by enabling the pursuit of the most innovative and advanced cancer research and by facilitating collaborations between science and business.
The Prize for young investigators provides early-stage funding opportunities to New York scientists with innovative ideas in cancer research. The program surrounding the Prize is a catalyst in bridging the gap between the academic scientific community and the business community.
SIDI CHEN, PHD
CHRISTINE IOK IN CHIO, PHD
MARCIN IMIELINSKI, MD, PHD
LILIAN KABECHE, PHD
ELENA PISKOUNOVA, PHD
XUEBING WU, PHD
THE PERSHING SQUARE FOUNDATION/ BUSINESS WIRE – The Pershing Square Sohn Cancer Research Alliance (PSSCRA) today announced the opening of applications for the 2022 Pershing Square Sohn Prize for Young Investigators in Cancer Research. The prize of $200,000 per year for three years is awarded annually to at least six New York City area-based scientists. The prize empowers researchers to pursue novel, high-risk/high-reward cancer research at a stage when traditional funding is lacking.
“With cancer genomics and single-cell technologies becoming a reality, along with advances in immunotherapy, metabolic targets and next-generation sequencing data, the pursuit of basic science alongside applied engineering has never been so opportune. Novel treatment strategies will in this way yield biological discoveries, and vice versa. We are proud to support early-career scientists driven by research which has the potential to activate state-of-the-art clinical treatment while revealing new scientific insights,” said Pershing Square Foundation Trustee Neri Oxman. “We look forward to reviewing the applications as we continue to grow our PSSCRA community.”
On Tuesday, October 19th, 2021, the Pershing Square Sohn Cancer Research Alliance held its Fifth Annual Pershing Square Sohn Retreat at the Simons Foundation in Manhattan, New York.
The Retreat highlighted the 2018 Pershing Square Sohn Prize winners who had just finished their third and final year of funding. These seven bold and creative scientists presented their research supported by the Prize to their peers, with robust Q&A discussions with guests in attendance both in-person and virtually via Zoom. The day concluded with fireside chat with an accomplished leader in academia and industry, Michel Sadelain, MD, PhD, the Stephen and Barbara Friedman Chair and Director of the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center, as well as the Scientific Co-Founder of Juno Therapeutics and Member of PSSCRA’s Scientific Review Council. The Pershing Square Foundation President and Pershing Square Sohn Cancer Research Alliance Co-Founder and Executive Director Olivia Tournay Flatto, PhD moderated the discussion.
Bill Ackman, Co-Founder. The Pershing Square Foundation